Is CGON or BNTX more profitable?

CG Oncology has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% BioNTech -44.39% -5.30% -4.62%

Does the media favor CGON or BNTX?

In the previous week, CG Oncology had 1 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for CG Oncology and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat CG Oncology's score of 0.69 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or VTRS more profitable?

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Viatris -2.04% 19.04% 7.62%

Does the media prefer CGON or VTRS?

In the previous week, CG Oncology had 5 more articles in the media than Viatris. MarketBeat recorded 7 mentions for CG Oncology and 2 mentions for Viatris. Viatris' average media sentiment score of 1.09 beat CG Oncology's score of 0.69 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CGON or GMAB?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,517.30 -$160.99M -$2.33 N/A Genmab A/S $3.72B 4.86 $963M $1.32 21.95

Is CGON or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Genmab A/S 21.05% 15.34% 8.94%

Does the media prefer CGON or GMAB?

In the previous week, Genmab A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 11 mentions for Genmab A/S and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.69 beat Genmab A/S's score of 0.42 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASND or CGON?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Ascendis Pharma A/S's average media sentiment score of 0.87 beat CG Oncology's score of 0.69 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CGON or BBIO?

In the previous week, BridgeBio Pharma had 22 more articles in the media than CG Oncology. MarketBeat recorded 29 mentions for BridgeBio Pharma and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.69 beat BridgeBio Pharma's score of 0.66 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

CG Oncology (CGON) Competitors

$69.50 -3.50 (-4.79%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$70.00 +0.50 (+0.72%)

As of 04:13 AM Eastern

Compare

CGON vs. BNTX, VTRS, GMAB, ASND, and BBIO

Should you buy CG Oncology stock or one of its competitors? MarketBeat compares CG Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CG Oncology include BioNTech (BNTX), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

How does CG Oncology compare to BioNTech?

CG Oncology (NASDAQ:CGON) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

In the previous week, CG Oncology had 1 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for CG Oncology and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat CG Oncology's score of 0.69 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
BioNTech	-44.39%	-5.30%	-4.62%

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 17.59%. BioNTech has a consensus price target of $129.13, suggesting a potential upside of 41.03%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

CG Oncology has higher earnings, but lower revenue than BioNTech. CG Oncology is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,517.30	-$160.99M	-$2.33	N/A
BioNTech	$3.25B	7.13	-$1.29B	-$5.88	N/A

CG Oncology has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioNTech beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Viatris?

CG Oncology (NASDAQ:CGON) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, CG Oncology had 5 more articles in the media than Viatris. MarketBeat recorded 7 mentions for CG Oncology and 2 mentions for Viatris. Viatris' average media sentiment score of 1.09 beat CG Oncology's score of 0.69 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology presently has a consensus target price of $81.73, indicating a potential upside of 17.59%. Viatris has a consensus target price of $17.50, indicating a potential upside of 0.98%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Viatris	-2.04%	19.04%	7.62%

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CG Oncology has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,517.30	-$160.99M	-$2.33	N/A
Viatris	$14.30B	1.41	-$3.51B	-$0.26	N/A

CG Oncology has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

CG Oncology beats Viatris on 9 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

CG Oncology (NASDAQ:CGON) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Genmab A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 11 mentions for Genmab A/S and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.69 beat Genmab A/S's score of 0.42 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology presently has a consensus target price of $81.73, indicating a potential upside of 17.59%. Genmab A/S has a consensus target price of $38.21, indicating a potential upside of 31.86%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

CG Oncology has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Genmab A/S	21.05%	15.34%	8.94%

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,517.30	-$160.99M	-$2.33	N/A
Genmab A/S	$3.72B	4.86	$963M	$1.32	21.95

Summary

Genmab A/S beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Ascendis Pharma A/S has a net margin of 57.87% compared to CG Oncology's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
CG Oncology	N/A	-23.33%	-22.24%

Ascendis Pharma A/S presently has a consensus price target of $295.67, suggesting a potential upside of 13.81%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 17.59%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. CG Oncology is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.90	-$258M	$8.67	29.97
CG Oncology	$4.04M	1,517.30	-$160.99M	-$2.33	N/A

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 7 articles in the media. Ascendis Pharma A/S's average media sentiment score of 0.87 beat CG Oncology's score of 0.69 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.6% of CG Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does CG Oncology compare to BridgeBio Pharma?

CG Oncology (NASDAQ:CGON) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

CG Oncology has higher earnings, but lower revenue than BridgeBio Pharma. CG Oncology is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,517.30	-$160.99M	-$2.33	N/A
BridgeBio Pharma	$502.08M	31.32	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 22 more articles in the media than CG Oncology. MarketBeat recorded 29 mentions for BridgeBio Pharma and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.69 beat BridgeBio Pharma's score of 0.66 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CG Oncology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
BridgeBio Pharma	-124.42%	N/A	-65.81%

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 17.59%. BridgeBio Pharma has a consensus price target of $95.21, indicating a potential upside of 18.57%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats CG Oncology on 10 of the 16 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.44B	$3.67B	$6.97B	$12.67B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-29.83	21.07	27.19	24.05
Price / Sales	1,517.30	300.81	578.62	112.08
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	7.45	8.39	10.76	6.23
Net Income	-$160.99M	$23.83M	$3.59B	$331.94M
7 Day Performance	-7.63%	-3.70%	-1.91%	-1.65%
1 Month Performance	15.01%	3.04%	2.24%	-1.03%
1 Year Performance	144.20%	42.73%	23.83%	17.10%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	3.3464 of 5 stars	$69.50 -4.8%	$81.73 +17.6%	+166.5%	$6.44B	$4.04M	N/A	61	Insider Trade
BNTX BioNTech	4.5273 of 5 stars	$94.29 +0.4%	$129.56 +37.4%	-18.6%	$23.84B	$3.25B	N/A	7,807	Positive News
VTRS Viatris	2.4577 of 5 stars	$16.96 +1.0%	$17.50 +3.2%	+90.9%	$19.75B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.5188 of 5 stars	$29.18 +4.2%	$38.21 +31.0%	+32.5%	$18.19B	$3.72B	22.11	3,029	Analyst Revision Gap Up
ASND Ascendis Pharma A/S	4.383 of 5 stars	$266.97 -0.4%	$295.67 +10.7%	+48.1%	$16.65B	$814.57M	30.79	1,189	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. BNTX, VTRS, GMAB, ASND, and BBIO

How does CG Oncology compare to BioNTech?

Summary

How does CG Oncology compare to Viatris?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Summary

How does CG Oncology compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. BNTX, VTRS, GMAB, ASND, and BBIO

How does CG Oncology compare to BioNTech?

Does the media favor CGON or BNTX?

Is CGON or BNTX more profitable?

Do analysts recommend CGON or BNTX?

Which has stronger earnings and valuation, CGON or BNTX?

Which has more volatility and risk, CGON or BNTX?

Do institutionals and insiders hold more shares of CGON or BNTX?

Summary

How does CG Oncology compare to Viatris?

Does the media prefer CGON or VTRS?

Do analysts recommend CGON or VTRS?

Is CGON or VTRS more profitable?

Do institutionals & insiders have more ownership in CGON or VTRS?

Which has stronger valuation & earnings, CGON or VTRS?

Which has more risk and volatility, CGON or VTRS?

Summary

How does CG Oncology compare to Genmab A/S?

Does the media prefer CGON or GMAB?

Do analysts prefer CGON or GMAB?

Which has more volatility and risk, CGON or GMAB?

Is CGON or GMAB more profitable?

Do insiders and institutionals have more ownership in CGON or GMAB?

Which has better valuation & earnings, CGON or GMAB?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Is ASND or CGON more profitable?

Do analysts rate ASND or CGON?

Which has higher earnings and valuation, ASND or CGON?

Does the media refer more to ASND or CGON?

Do insiders and institutionals have more ownership in ASND or CGON?

Which has more volatility and risk, ASND or CGON?

Summary

How does CG Oncology compare to BridgeBio Pharma?

Which has higher earnings and valuation, CGON or BBIO?

Does the media prefer CGON or BBIO?

Which has more volatility and risk, CGON or BBIO?

Do insiders and institutionals believe in CGON or BBIO?

Is CGON or BBIO more profitable?

Do analysts rate CGON or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools